Evidence map›Paper›PMID 27446537›Full record

ArticleBiomedical reports2016

Autoimmune vitiligo in rheumatic disease in the mestizo Mexican population.

Esperanza Avalos-Díaz, Elena Pérez-Pérez, Mayra Rodríguez-Rodríguez, María-Guadalupe Pacheco-Tovar, Rafael Herrera-Esparza

Abstract read
In one paragraph

Article in Biomedical reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Multiple autoimmunity and epitope spreading in monozygotic twins.Journal of translational autoimmunity · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Esperanza Avalos-DíazDepartment of Immunology, UACB, Universidad Autónoma de Zacatecas, Zacatecas 98040, Mexico.
Elena Pérez-PérezDepartment of Immunology, UACB, Universidad Autónoma de Zacatecas, Zacatecas 98040, Mexico.
Mayra Rodríguez-RodríguezDepartment of Immunology, UACB, Universidad Autónoma de Zacatecas, Zacatecas 98040, Mexico.
María-Guadalupe Pacheco-TovarDepartment of Immunology, UACB, Universidad Autónoma de Zacatecas, Zacatecas 98040, Mexico.
Rafael Herrera-EsparzaDepartment of Immunology, UACB, Universidad Autónoma de Zacatecas, Zacatecas 98040, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vitiligo is a chronic disease characterized by the dysfunction or destruction of melanocytes with secondary depigmentation. The aim of the present study was to determine the prevalence of vitiligo associated with autoimmune rheumatic diseases. The clinical records from a 10-year database of patients with rheumatic diseases and associated vitiligo was analysed, with one group of patients having autoimmune rheumatic disease and another non-autoimmune rheumatic disease. Available serum samples were used to assess the anti-melanocyte antibodies. A total of 5,251 individual clinical files were archived in the last 10 years, and these patients underwent multiple rheumatology consultations, with 0.3% of the group presenting with vitiligo. The prevalence of vitiligo in the autoimmune rheumatic disease group was 0.672%, which was mainly associated with lupus and arthritis. However, patients with more than one autoimmune disease had an increased relative risk to develop vitiligo, and anti-melanocyte antibodies were positive in 92% of these patients. By contrast, the prevalence was 0.082% in the group that lacked autoimmune rheumatic disease and had negative autoantibodies. In conclusion, the association between vitiligo and autoimmune rheumatic diseases was relatively low. However, the relative risk increased when there were other autoimmune comorbidities, such as thyroiditis or celiac disease. Therefore, the presence of multiple autoimmune syndromes should be suspected.

Indexed as

autoimmunityrheumatic diseasevitiligo

Identifiers

PMID27446537
PMCPMC4950649

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.